"Love of invention will never end." - Carl Benz Learn more about us as we continue to pioneer the future of driving excellence. Data privacy: mb4.me/provider_privacy Imprint: Mercedes-Benz AG Mercedesstraße 120 D-70372 Stuttgart Deutschland Tel.: +49 7 11 17-0 E-Mail: dialog.mb@mercedes-benz.com Vertreten durch den Vorstand: Ola Källenius (Vorsitzender), Jörg Burzer, Renata Jungo Brüngger, Sabine Kohleisen, Harald Wilhelm, Markus Schäfer, Britta Seeger Vorsitzender des Aufsichtsrats: Martin Brudermüller Handelsregister beim Amtsgericht Stuttgart, Nr. HRB 762873 Umsatzsteueridentifikationsnummer: DE321281763
Atleos (NYSE: NATL) is a leader in expanding self-service financial access, with industry-leading ATM expertise and experience, unrivalled operational scale including the largest independently-owned ATM network, always-on global services and constant innovation. Atleos improves operational efficiency for financial institutions, drives footfall for retailers and enables digital-first financial self-service experiences for consumers. Atleos is headquartered in Atlanta, Georgia, with approximately 20,000 employees globally.
BDO is a leading professional services organisation and are global leaders of the mid-tier. Operating in over 166 countries, our team of over 115,600 multi-functional experts work to provide business advice, that is driven by practical experience and up-to-date knowledge. With an objective of delivering an exceptional experience to each of our clients, we are continuously embracing newer technologies and approaches to deliver solutions that are best suited to address current business needs, as much as being future-ready. We are proud to be a people-powered business that focuses on deriving value through innovation and strong people relations. BDO India, is a key member of the global BDO organisation, employing over 9500 professionals across 18 offices in 12 key cities - Ahmedabad, Bengaluru, Chandigarh, Chennai, Coimbatore, Delhi NCR, Goa, Hyderabad, Kochi, Kolkata, Mumbai and Pune. We offer Assurance, Tax, Advisory, Business Services & Outsourcing, and Digital Services to both domestic and international clients across a range of industries. With an inherent culture of putting people first, we demonstrate our true purpose of being an organisation of People Helping People.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.